EAGLE PHARMACEUTICALS, INC.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $316.6M | $171.5M | $187.8M | $195.9M | $213.3M | $236.7M |
| Operating income | $81.0M | $2.8M | $33.0M | $21.8M | $36.6M | $74.0M |
| Net income | $35.6M | −$8.6M | $12.0M | $14.3M | $31.9M | $51.9M |
| Total assets | $406.2M | $253.7M | $253.2M | $254.6M | $238.6M | $270.1M |
| Total liabilities | $172.6M | $77.3M | $67.2M | $75.4M | $77.8M | — |
| Equity | $233.6M | $176.5M | $186.0M | $179.2M | $160.8M | $179.1M |
| EPS (diluted) | $2.73 | $-0.66 | $0.87 | $1.01 | $2.09 | $3.27 |
| Shares out. | 12.7M | 13.1M | 13.2M | 13.9M | 14.9M | 15.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- 25.6%
- Net margin
- 11.3%
- Return on equity
- 15.3%
- Return on assets
- 8.8%
- Return on capital (ROCE)
- 27.4%
- Liabilities / assets
- 42.5%
- Debt / equity
- 0.74×
- Book value / share
- $18.39
- Revenue growth (YoY)
- 84.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- 4.91safe
- Accruals / assets
- −3.7%clean
- Beneish M-Score
- -1.70elevated
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 7 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Beneish M-Score elevated — earnings-manipulation screen flag
- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 13, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 9, 2024
- NT 10-Qmissed a reporting deadline ↗May 10, 2024
- NT 10-Kmissed a reporting deadline ↗Mar 18, 2024
- NT 10-Qmissed a reporting deadline ↗Nov 9, 2023
- NT 10-Kmissed a reporting deadline ↗Mar 17, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- J. Goldman & Co LpPassive (13G)Aug 14, 2025
- Nantahala Capital Management, LlcPassive (13G)Aug 14, 2025
- Nantahala Capital Partners Limited PartnershipPassive (13G)Feb 19, 2025
- Union Square Park Capital Management, LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Cahill Brian JosephOfficer — Chief Financial Officer | Dec 18, 2023 | Tax withholding | 452 | $4.76 |
| Tarriff ScottOfficer — CEO | Nov 1, 2023 | Sell | 10,925 | $13.82 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Modified shareholder rightsDec 2, 2024
- Changed auditorNov 27, 2024
- Delisting / listing-standard noticeNov 15, 2024
- Director / officer change · Regulation FD disclosure · Other material eventNov 12, 2024
- Entered a material agreement · Modified shareholder rights · Amended charter or bylaws · Regulation FD disclosureOct 31, 2024
- Results of operations · Delisting / listing-standard notice · Prior financials not reliable (restatement) · Other material eventOct 2, 2024
- Entered a material agreement · New financial obligation · Delisting / listing-standard notice · Regulation FD disclosureAug 27, 2024
- Other material eventAug 5, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13GAug 14, 2025
- SCHEDULE 13G/AAug 14, 2025
- SCHEDULE 13GFeb 19, 2025
- SCHEDULE 13G/AFeb 19, 2025
- SCHEDULE 13G/AFeb 14, 2025
- 15-12GJan 24, 2025
- EFFECTDec 9, 2024
- 8-KFORM 8-KDec 2, 2024
- RWNov 27, 2024
- POS AMNov 27, 2024
- S-8 POSNov 27, 2024
- S-8 POSNov 27, 2024
- S-8 POSNov 27, 2024
- S-8 POSNov 27, 2024
- S-8 POSNov 27, 2024
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.